Original research / AJJ Medtech
AJJ Medtech’s First India Order Meets a Nine-Month Cash Drain
AJJ Medtech has secured its first overseas order for its branded hemodialyzers. Contract conditions and its September financial position mean the order has yet to establish a dividend case.
AJJ Medtech Holdings (SGX: 584) has secured its first overseas commercial purchase order for its branded hemodialyzers: 15,000 units for a customer in India. Announced on 18 November 2026, it follows an initial Singapore order in October. For dividend investors, the question is whether these orders can become collected cash while the group is still reporting losses. [S1, p. 1]
An order, with conditions attached
The India purchase order calls for a 10% advance payment and the remaining 90% before dispatch. That payment structure could limit the cash tied up in a completed sale, but the announcement does not disclose an order value or say the payments have been collected. Acceptance, supply, delivery and revenue recognition remain subject to contractual and regulatory requirements. [S1, p. 1]
AJJ is also developing a proposed distribution framework with the Indian customer. Its illustration of 120,000 units over two years assumes repeated quarterly purchases; it is neither a committed minimum nor an order backlog. Singapore product registration does not authorise sales in India, where applicable product and import approvals remain necessary. [S1, p. 1] [S1, p. 2]
The company says this first overseas order alone is not expected to have a material effect on earnings per share or net tangible assets per share for the year ending December 2026. Investors therefore have a commercial milestone, not evidence of revenue at scale. [S1, p. 2]
The financial starting point
AJJ’s unaudited results for the nine months ended 30 September 2026 predate the India order. Group revenue was S$1.817 million, down from S$2.251 million a year earlier. The loss attributable to owners widened to S$1.944 million from S$1.706 million. Healthcare products and services supplied most of the reported revenue, at S$1.674 million. [S2, p. 2] [S2, p. 12]
Cash conversion was also under pressure. Net cash used in operating activities was S$545,000, compared with S$297,000 in the prior nine-month period. Cash and bank balances stood at S$54,000 on 30 September, down from S$414,000 at the previous year-end; net current liabilities were S$4.110 million. These are reporting-date figures, not a claim about today’s cash balance. [S2, p. 4] [S2, p. 8]
The cash-flow statement shows that S$661,000 of placement subscription money had already been received by 30 September. Although the placement shares were allotted on 29 October, the company says that allotment did not bring in another S$661,000 in October. Treating it as fresh cash on top of the reported funding would overstate the cushion shown by these disclosures. [S2, p. 8] [S2, p. 15] [S2, p. 16]
What would change the dividend picture?
No dividend was declared or recommended for the nine-month period. AJJ cited its losses, cash needs and the priority of preserving liquidity for operations. That makes the India order relevant as a test of execution rather than a reason to expect a payout from this announcement. [S2, p. 21]
The evidence to watch is whether the company receives the advance, secures the approvals needed for supply, delivers the units and converts the order into recognised revenue and operating cash. Repeat orders would strengthen the commercial story, but the proposed framework does not guarantee them. Until those steps are reported alongside improved finances, the filings do not establish a dividend-paying trajectory. [S1, p. 1] [S1, p. 2] [S2, p. 8]